Antibodies: Timeline of key events

Mouseover the event title for a more detailed description of the event (if available). To search for particular terms in the description of the event enter the term in the box below 'Event' on the table and press 'enter'. Alternatively use the dropdown lists to filter by Person, Place or Science. Click here to clear the filter.

It was the first time tyhe FDA approved an immune checkpoint inhibitor for the treatment of lung cancer. The drug was developed by Merck & Co.2016-10-24T00:00:00+0000Evidence collected from randomised, doublice-blind, placebo controled study of 27,000 patients in 49 countries between Feb 2013 and June 2015. MS Sabatine, et al, 'Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease', NEJM, 2017, DOI: 10.1056/NEJMoa1615664.2017-03-17T00:00:00+0000Developed by EMD Serono avelumab is a PD-L1 blocking monoclonal antibody. It was the first FDA approved product to treat metastatic Merckel cell carcinoma.2017-03-23T00:00:00+0000
Date Event People Places Sciences
24 Oct 2016FDA approved pembrolizumab (Keytruda®) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test. MerckImmune checkpoint inhibitors, Cancer immunotherapy, Oncology, Monoclonal antibodies
17 Mar 2017Monoclonal antibody shown to effectively cut cholesterol levels, thereby preventing heart attacks and strokes SabatineMonoclonal antibodies, Cardiovascular
23 Mar 2017US FDA granted accelerated approval to avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinomaEMD SeronoImmune checkpoint inhibitors, Cancer immunotherapy, Oncology, Monoclonal antibodies

24 Oct 2016

FDA approved pembrolizumab (Keytruda®) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.

17 Mar 2017

Monoclonal antibody shown to effectively cut cholesterol levels, thereby preventing heart attacks and strokes

23 Mar 2017

US FDA granted accelerated approval to avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma